ArticleProceedings of the National Academy of Sciences of the United States of America2013
Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- The metabolic role of corticotropin-releasing hormone receptor 2 and its UCN peptides: emerging therapeutic potential.Skeletal muscle · 2025Review
- Urocortin Role in Ischemia Cardioprotection and the Adverse Cardiac Remodeling.International journal of molecular sciences · 2021Review
- Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance.Journal of cachexia, sarcopenia and muscle · 2021Article
- Article
- UCN2: a new candidate influencing pancreatic β-cell adaptations in pregnancy.The Journal of endocrinology · 2020Article
- Mapping Changes of Whole Brain Blood Flow in Rats with Myocardial Ischemia/Reperfusion Injury Assessed by Positron Emission Tomography.Current medical science · 2019Article
- Role of corticotropin-releasing factor on bladder function in rats with psychological stress.Scientific reports · 2019Article
- Metabolic Association between Leptin and the Corticotropin Releasing Hormone.Endocrine, metabolic & immune disorders drug targets · 2019Article
- RNA SEQ Analysis Indicates that the AE3 ClScientific reports · 2017Article
- Hypoxia decreases creatine uptake in cardiomyocytes, while creatine supplementation enhances HIF activation.Physiological reports · 2017Article
- Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction.The Journal of experimental medicine · 2017Article
- Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway.Pharmacological research · 2016Article
- Unique Features of Cortical Bone Stem Cells Associated With Repair of the Injured Heart.Circulation research · 2015Article
- The Modulation of Cardiac Contractile Function by the Pharmacological and Toxicological Effects of Urocortin2.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
- Comparative effects of urocortins and stresscopin on cardiac myocyte contractility.Journal of molecular and cellular cardiology · 2015Article
- AMPK: energy sensor and survival mechanism in the ischemic heart.Trends in endocrinology and metabolism: TEM · 2015Review
- Targeting AMPK for cancer prevention and treatment.Oncotarget · 2015Review
- Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle.The Journal of endocrinology · 2014Article
- The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury.The Journal of clinical investigation · 2014Article
- Autophagy, a process within reperfusion injury: an update.International journal of clinical and experimental pathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urocortin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with high affinity to type 2 CRF receptors (CRFR2) on cardiomyocytes and confers protection against ischemia/reperfusion. The mechanisms by which the Ucn2-CRFR2 axis mitigates against ischemia/reperfusion injury remain incompletely delineated. Activation of AMP-activated protein kinase (AMPK) also limits cardiac damage during ischemia/reperfusion. AMPK is classically activated by alterations in cellular energetics; however, hormones, cytokines, and additional autocrine/paracrine factors also modulate its activity. We examined the effects of both the endogenous cardiac Ucn2 autocrine/paracrine pathway and Ucn2 treatment on AMPK regulation. Ucn2 treatment increased AMPK activation and downstream acetyl-CoA carboxylase phosphorylation and glucose uptake in isolated heart muscles. These actions were blocked by the CRFR2 antagonist anti-sauvagine-30 and by a PKCε translocation-inhibitor peptide (εV1-2). Hypoxia-induced AMPK activation was also blunted in heart muscles by preincubation with either anti-sauvagine-30, a neutralizing anti-Ucn2 antibody, or εV1-2. Treatment with Ucn2 in vivo augmented ischemic AMPK activation and reduced myocardial injury and cardiac contractile dysfunction after regional ischemia/reperfusion in mice. Ucn2 also directly activated AMPK in ex vivo-perfused mouse hearts and diminished injury and contractile dysfunction during ischemia/reperfusion. Thus, both Ucn2 treatment and the endogenous cardiac Ucn2 autocrine/paracrine pathway activate AMPK signaling pathway, via a PKCε-dependent mechanism, defining a Ucn2-CRFR2-PKCε-AMPK pathway that mitigates against ischemia/reperfusion injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.